Skip to main content
Equibles

Meredith Manning

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Meredith Manning

The company reported in an 8-K filed May 18, 2026 that Meredith Manning resigned as Chief Commercial Officer, effective May 18, 2026. The proxy statement of the company reports total compensation of $7,783,050 for Meredith Manning in fiscal 2024, including a base salary of $415,179. Meredith Manning has spoken on 1 earnings call across 1 company, most recently on February 25, 2026.

“each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer of the Company, in each case, effective as of the Effective Time.”
Company Form 8-K, filed May 18, 2026 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Organization not stated

    Proxy statement

    Start not stated–2026-05-18

Company network

Recorded roles and call appearances connecting this person to public companies.

Company

1 appearance Latest appearance 2026-02-25

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 — $415,179 $7,783,050

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.